Extensive-stage Small-cell Lung Cancer
Conditions
Brief summary
This is an open-label, single arm Phase II study designed to observe and evaluate the efficacy and safety of sequential thoracic radiotherapy in the first-line treatment of extensive small cell lung cancer with chemotherapy combined with approved PD-1/PD-L1 inhibitors.
Detailed description
This study a single arm prospective phase II study. All the enrolled patients will be patients with ES-SCLC who did not have PD after 4-6 cycle of platinum-based chemotherapy in combination with an PD-1/PD-L1 inhibitors. Then, those enrolled patients would be treated with thoracic radiotherapy concurrently with PD-1/PD-L1 maintenance therapy.
Interventions
RADIATIONThoracic Radiotherapy
Thoracic Radiotherapy (45Gy /1.5Gy/bid/3w)
Sponsors
Henan Cancer Hospital
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Age between18 years and 75 years. 2. Histologic or cytologic confirmation of extensive-stage small cell lung cancer. 3. Initially treated patients with extensive SCLC showed no disease progression after 4-6 cycles of chemotherapy combined with PD-1/PD-L1 inhibitors. 4. Presence of at least one measurable lesion (according to RECIST v1.1). 5. ECOG performance status of 0 or 1. 6. Life expectancy of at least 3 months. 7. Adequate bone marrow, liver and kidney function. 8. Adequate pulmonary function with FEV1 \>1 L or \>30 % of predicted value and DLCO \>30 % of predicted value
Exclusion criteria
1. Previous T cell co-stimulation or immune checkpoint therapy. 2. Previous received chemoradiotherapy for limited-stage SCLC. 3. Central nervous system metastasis with clinical symptoms. 4. Multiple liver metastases (patients with isolated liver metastases, metastatic lesions \< 3cm could be included). 5. Patients with spinal cord compression. 6. Idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonia or idiopathic pneumonia, or evidence of active pneumonia during screening (patients with active pulmonary tuberculosis couldn't be enrolled). 7. Have received any other investigational drug treatment or participated in another interventional clinical study within 4 weeks prior to signing the informed consent. 8. In the 5 years prior to the study, subjects had prior or concurrent malignancies requiring active treatment. 9. Subjects with any severe and/or uncontrolled disease (hypertension, heart disease, infection, cirrhosis, active hepatitis, AIDS, third space effusion). 10. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation. 11. Severe allergic reactions to any of the monoclonal antibodies are known to occur.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| progression-free survival rate at 6-month | 12 months after last patient entry | PFS is defined as the period from the start of receiving the first line chemotherapy plus PD-1/PD-L1 inhibitor to disease progression. |
Countries
China
Contacts
Primary ContactYang Liu
Outcome results
None listed